PCI Pharma Services to invest $50M to boost production at Illinois campus
Philadelphia-based contract manufacturer PCI Pharma announced on Tuesday plans to invest $50 million to build a new 200,000-square-foot manufacturing facility at its campus in the city of Rockford, Illinois.
According to a statement from the company, the new facility will have over 20 manufacturing suites and the ability to assemble and package vials, pre-filled syringes and other injectable medicines. It will also produce medicines designed to treat diabetes and obesity as well as manufacture drugs for oncology and autoimmune diseases.
PCI’s new facility, which is expected to bring in 250 jobs over the next two years, should be up and running in the summer of 2024, with more growth anticipated over the next three to five years.
According to PCI’s SVP of commercial packaging technology Gil Valadez in an email to Endpoints News, the new site will also have cold storage, labeling, assembly and packaging capabilities.
“The need for injectable drug-delivery device combination product capacity and expertise is critical, and we are responding with a world-class facility to address the future demands of our global clients so they can focus on developing therapies to improve the lives of patients with serious chronic conditions,” said PCI Pharma Service CEO Salim Haffar, in a release.
Last year, the CDMO embarked on several expansions across both sides of the Atlantic Ocean. In May, it dropped $100 million into its aseptic liquid fill-finish and sterile lyophilization technology at its campus in Bedford, NH, which it bought at the end of 2021. That expansion will add a 50,000-square-foot facility with the ability to pump out 400 vials per minute.
In the summer of last year, it also decided to expand its manufacturing facility in the town of Tredegar, Wales, with that expansion designed to help the company keep pace with the production of oncology therapies. The expansion will also include two new facilities dedicated to manufacturing and packaging solid oral-dose tablets and capsules.